Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma is assigned a higher cost of capital, reflecting cash overhang and potential partnership needs. As a self-commercializing model is assumed, the valuation is based on a discounted cash flow analysis using a 17.6% WACC and a 4.0x exit multiple on 2036 estimates. Near-term focus is on Tivoxavir marboxil, with a single-dose influenza virus challenge trial in progress, as the company emphasizes seasonal influenza prophylaxis while preserving potential options for bird flu and stockpile inclusion.

Traws Pharma is facing potential funding overhang in 1Q27 which may require them to move forward with a new lead candidate. Their hantavirus/Ebola antiviral program, though adding longer-term optionality, currently holds low value due to its early development status, lack of later-stage clinical data, and uncertainty around commercial opportunities. Despite the ongoing regulatory hold on their lead candidate TXM, management is actively working on resolving the issue and a successful outcome would greatly de-risk the stock.